Cell and gene therapy for severe heart failure patients: The time and place for Pim-1 kinase

Expert Review of Cardiovascular Therapy

Volumn 11, Issue 8, 2013, Pages 949-957

  Siddiqi, Sailay ^a,b   Sussman, Mark A ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

cardiac progenitor cell gene therapy; cell therapy; heart failure; Pim 1; senescence

Indexed keywords

PROTEIN KINASE PIM 1;

ARTICLE; CELL THERAPY; DISEASE SEVERITY; GENE THERAPY; HEART FAILURE; HUMAN; MUSCLE CELL; ONCOGENE; ONCOGENE PIM 1; PHENOTYPE; STEM CELL TRANSPLANTATION;

ANIMALS; APOPTOSIS; CARDIOMEGALY; CELL AGING; CELL- AND TISSUE-BASED THERAPY; GENETIC THERAPY; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-PIM-1; SEVERITY OF ILLNESS INDEX; STEM CELLS;

EID: 84887632221     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2013.814830     Document Type: Article

References (70)

1. Willerson JT, Perin EC, Ellis SG et al.; Cardiovascular Cell Therapy Research Network (CCTRN). Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design. Am. Heart J. 160(2), 215-223 (2010
2. Strauer BE, Brehm M, Zeus T et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106(15), 1913-1918 (2002
3. Perin EC, Willerson JT, Pepine CJ et al.; Cardiovascular Cell Therapy Research Network (CCTRN). Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: The FOCUSCCTRN trial. JAMA 307(16), 1717-1726 (2012
4. Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur. Heart J. 30(24), 2978-2984 (2009
5. Leistner DM, Fischer-Rasokat U, Honold J et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): Final 5-year results suggest long-term safety and efficacy. Clin. Res. Cardiol. 100(10), 925-934 (2011
6. Assmus B, Schächinger V, Teupe C et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 106(24), 3009-3017 (2002
7. Zeng L, Hu Q, Wang X et al. Bioenergetic and functional consequences of bone marrow-derived multipotent progenitor cell transplantation in hearts with postinfarction left ventricular remodeling. Circulation 115(14), 1866-1875 (2007
8. Bolli R, Chugh AR, D'Amario D et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): Initial results of a randomised phase 1 trial. Lancet 378(9806), 1847-1857 (2011
9. Makkar RR, Smith RR, Cheng K et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. Lancet 379(9819), 895-904 (2012
10. Kajstura J, Rota M, Cappetta D et al. Cardiomyogenesis in the aging and failing human heart. Circulation 126(15), 1869-1881 (2012
11. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. J. Clin. Invest. 123(3), 966-972 (2013
12. Mallat Z, Fornes P, Costagliola R et al. Age and gender effects on cardiomyocyte apoptosis in the normal human heart. J. Gerontol. A Biol. Sci. Med. Sci. 56(11), M719-M723 (2001
13. Duque G. Apoptosis in Cardiovascular Aging Research: Future Directions. Am. J. Geriatr. Cardiol. 9(5), 263-264 (2000
14. Grodzicki T, Michalewicz L, Messerli FH. Aging and essential hypertension: Effect of left ventricular hypertrophy on cardiac function. Am. J. Hypertens. 11(4 Pt 1), 425-429 (1998
15. Lakatta EG. Introduction: Chronic heart failure in older persons. Heart Fail. Rev. 7(1), 5-8 (2002
16. Patel MB, Sonnenblick EH. Age Associated Alterations in Structure and Function of the Cardiovascular System. Am. J. Geriatr. Cardiol. 7(2), 15-22 (1998
17. Sussman MA, Anversa P. Myocardial aging and senescence: Where have the stem cells gone? Annu. Rev. Physiol. 66, 29-48 (2004
18. Chimenti C, Kajstura J, Torella D et al. Senescence and death of primitive cells and myocytes lead to premature cardiac aging and heart failure. Circ. Res. 93(7), 604-613 (2003
19. Beltrami AP, Cesselli D, Beltrami CA. Stem cell senescence and regenerative paradigms. Clin. Pharmacol. Ther. 91(1), 21-29 (2012
20. Cesselli D, Beltrami AP, D'Aurizio F et al. Effects of age and heart failure on human cardiac stem cell function. Am. J. Pathol. 179(1), 349-366 (2011
21. Kajstura J, Rota M, Urbanek K et al. The telomere-telomerase axis and the heart. Antioxid. Redox Signal. 8(11-12), 2125-2141 (2006
22. Torella D, Rota M, Nurzynska D et al. Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ. Res. 94(4), 514-524 (2004
23. Miura O, Miura Y, Nakamura N et al. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood 84(12), 4135-4141 (1994
24. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-Alpha activates multiple STAT proteins and upregulates proliferationassociated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 93(6), 1980-1991 (1999
25. Wierenga AT, Vellenga E, Schuringa JJ. Maximal STAT5-induced proliferation and self-renewal at intermediate STAT5 activity levels. Mol. Cell. Biol. 28(21), 6668-6680 (2008
26. Domen J, Von Lindern M, Hermans A, Breuer M, Grosveld G, Berns A. Comparison of the human and mouse PIM-1 cDNAs: Nucleotide sequence and immunological identification of the in vitro synthesized PIM-1 protein. Oncogene Res. 1(1), 103-112 (1987
27. Selten G, Cuypers HT, Berns A. Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J. 4(7), 1793-1798 (1985
28. Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS. Pim-1 protein expression is regulated by its 5'-untranslated region and translation initiation factor elF-4E. Cell Growth Differ. 8(12), 1371-1380 (1997
29. Losman JA, Chen XP, Vuong BQ, Fay S, Rothman PB. Protein phosphatase 2A regulates the stability of Pim protein kinases. J. Biol. Chem. 278(7), 4800-4805 (2003
30. Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS. Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene 26(35), 5145-5153 (2007
31. Mizuno K, Shirogane T, Shinohara A, Iwamatsu A, Hibi M, Hirano T. Regulation of Pim-1 by Hsp90. Biochem. Biophys. Res. Commun. 281(3), 663-669 (2001
32. Shay KP, Wang Z, Xing PX, McKenzie IF, Magnuson NS. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol. Cancer Res. 3(3), 170-181 (2005
33. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 17(15), 1841-1854 (2003
34. Yan B, Zemskova M, Holder S et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J. Biol. Chem. 278(46), 45358-45367 (2003
35. Didichenko SA, Spiegl N, Brunner T, Dahinden CA. IL-3 induces a Pim1- dependent antiapoptotic pathway in primary human basophils. Blood 112(10), 3949-3958 (2008
36. Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J. Biol. Chem. 274(26), 18659-18666 (1999
37. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim. Biophys. Acta 1593(1), 45-55 (2002
38. Bhattacharya N, Wang Z, Davitt C, McKenzie IF, Xing PX, Magnuson NS. Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 111(2), 80-95 (2002
39. Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, Möröy T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int. J. Biochem. Cell Biol. 38(3), 430-443 (2006
40. Bachmann M, Hennemann H, Xing PX, Hoffmann I, Möröy T. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25Cassociated kinase 1 (C-TAK1): A novel role for Pim-1 at the G2/M cell cycle checkpoint. J. Biol. Chem. 279(46), 48319-48328 (2004
41. Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 27(35), 4809-4819 (2008
42. Kim J, Roh M, Abdulkadir SA. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer 10, 248 (2010
43. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000
44. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expressionbased method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 100(17), 9991-9996 (2003
45. Poulsen CB, Borup R, Nielsen FC et al. Microarray-based classification of diffuse large B-cell lymphoma. Eur. J. Haematol. 74(6), 453-465 (2005
46. Hsi ED, Jung SH, Lai R et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: A Cancer and Leukemia Group B 59909 correlative science study. Leuk. Lymphoma 49(11), 2081-2090 (2008
47. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J. Natl. Cancer Inst. 95(9), 661-668 (2003
48. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849), 822-826 (2001
49. Reiser-Erkan C, Erkan M, Pan Z et al. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol. Ther. 7(9), 1352-1359 (2008
50. Warnecke-Eberz U, Bollschweiler E, Drebber U et al. Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases. Oncol. Rep. 20(3), 619-624 (2008
51. Dang CV, O'donnell KA, Juopperi T. The great MYC escape in tumorigenesis. Cancer Cell 8(3), 177-178 (2005
52. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 11(6), 709-719 (1999
53. Xu D, Allsop SA, Witherspoon SM et al. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis 32(4), 488-495 (2011
54. Hemann MT, Bric A, Teruya-Feldstein J et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 436(7052), 807-811 (2005
55. Jackson T, Allard MF, Sreenan CM, Doss LK, Bishop SP, Swain JL. The c-myc proto-oncogene regulates cardiac development in transgenic mice. Mol. Cell. Biol. 10(7), 3709-3716 (1990
56. Cottage CT, Neidig L, Sundararaman B et al. Increased mitotic rate coincident with transient telomere lengthening resulting from pim-1 overexpression in cardiac progenitor cells. Stem Cells 30(11), 2512-2522 (2012
57. Fischer KM, Din S, Gude N et al. Cardiac progenitor cell commitment is inhibited by nuclear Akt expression. Circ. Res. 108(8), 960-970 (2011
58. Sundararaman B, Avitabile D, Konstandin MH, Cottage CT, Gude N, Sussman MA. Asymmetric chromatid segregation in cardiac progenitor cells is enhanced by Pim-1 kinase. Circ. Res. 110(9), 1169-1173 (2012
59. Cottage CT, Bailey B, Fischer KM et al. Cardiac progenitor cell cycling stimulated by pim-1 kinase. Circ. Res. 106(5), 891-901 (2010
60. Tufan H, Zhang XH, Haghshenas N, Sussman MA, Cleemann L, Morad M. Cardiac progenitor cells engineered with Pim-1 (CPCeP) develop cardiac phenotypic electrophysiological properties as they are co-cultured with neonatal myocytes. J. Mol. Cell. Cardiol. 53(5), 695-706 (2012
61. Quijada P, Toko H, Fischer KM et al. Preservation of myocardial structure is enhanced by pim-1 engineering of bone marrow cells. Circ. Res. 111(1), 77-86 (2012
62. Fischer KM, Cottage CT, Wu W et al. Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase. Circulation 120(21), 2077-2087 (2009
63. Mohsin S, Khan M, Toko H et al. Human cardiac progenitor cells engineered with Pim-I kinase enhance myocardial repair. J. Am. Coll. Cardiol. 60(14), 1278-1287 (2012
64. Karantalis V, Schulman IH, Hare JM. Nitroso-redox imbalance affects cardiac structure and function. J. Am. Coll. Cardiol. 61(9), 933-935 (2013
65. Williams AR, Hatzistergos KE, Addicott B et al. Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 127(2), 213-223 (2013
66. Muraski JA, Rota M, Misao Y et al. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat. Med. 13(12), 1467-1475 (2007
67. Muraski JA, Fischer KM, Wu W et al. Pim-1 kinase antagonizes aspects of myocardial hypertrophy and compensation to pathological pressure overload. Proc. Natl. Acad. Sci. U.S.A. 105(37), 13889-13894 (2008
68. Borillo GA, Mason M, Quijada P et al. Pim-1 kinase protects mitochondrial integrity in cardiomyocytes. Circ. Res. 106(7), 1265-1274 (2010
69. Din S, Mason M, Völkers M et al. Pim-1 preserves mitochondrial morphology by inhibiting dynamin-related protein 1 translocation. Proc. Natl. Acad. Sci. U.S.A. 110(15), 5969-5974 (2013
70. Katare R, Caporali A, Zentilin L et al. Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ. Res. 108(10), 1238-1251 (2011